Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer
10.4068/cmj.2019.55.3.127
- Author:
Zhuan Zhuan MU
1
;
Xin ZHANG
;
Yan Song LIN
Author Information
1. Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, Beijing, China. linys@pumch.cn
- Publication Type:Review
- Keywords:
Thyroid Neoplasms;
Iodine Radioisotopes;
Molecular Imaging
- MeSH:
Humans;
Iodine Radioisotopes;
Iodine;
Molecular Imaging;
Nuclear Medicine;
Prognosis;
Thyroid Gland;
Thyroid Neoplasms
- From:Chonnam Medical Journal
2019;55(3):127-135
- CountryRepublic of Korea
- Language:English
-
Abstract:
Most differentiated thyroid cancer (DTC) patients have an excellent prognosis. However, about one-third of DTC patients with recurrent or metastatic disease lose the hallmark of specific iodine uptake initially or gradually and acquire radioactive iodine-refractory DTC (RAIR-DTC) with poor prognosis. Due to the potentially severe complications from unnecessarily repeated RAI therapy and encouraging progress of multiple targeted drugs for advanced RAIR-DTC patients, it has become crucial to identify RAIR-DTC early. In this review, we focus on the progress and controversies regarding the defining of RAIR-DTC, further with subsistent approaches and promising molecular nuclear medicine imaging in identifying RAIR-DTC, which may shed light on the proper management methodsof such patients.
